Establishment Labs EPS ESTA
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$1.31
- Latest quarter, Q2 FY26
- −$0.39
- Fiscal year 2025
- −$1.74
Establishment Labs' earnings per share was −$1.31 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.39.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.74 | n/a |
| FY2024 | −$2.98 | n/a |
| FY2023 | −$3.04 | n/a |
| FY2022 | −$3.07 | n/a |
| FY2021 | −$1.71 | n/a |
| FY2020 | −$1.66 | n/a |
| FY2019 | −$1.86 | n/a |
| FY2018 | −$1.24 | n/a |
| FY2017 | −$4.02 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.39 | n/a | −$1.31 | |
| Q1 FY26 | −$0.45 | n/a | −$1.49 | |
| Q4 FY25 | −$0.09 | n/a | −$1.74 | |
| Q3 FY25 | −$0.38 | n/a | −$2.84 | |
| Q2 FY25 | −$0.57 | n/a | −$3.05 | |
| Q1 FY25 | −$0.70 | n/a | −$3.10 | |
| Q4 FY24 | −$1.19 | n/a | −$2.98 | |
| Q3 FY24 | −$0.59 | n/a | −$2.58 | |
| Q2 FY24 | −$0.62 | n/a | −$3.11 | |
| Q1 FY24 | −$0.58 | n/a | −$3.14 | |
| Q4 FY23 | −$0.79 | n/a | −$3.04 | |
| Q3 FY23 | −$1.12 | n/a | −$2.80 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Establishment Labs' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ESTAEstablishment Labs | −$1.31 | |
| LMATLemaitre Vascular | $2.85 | +38% a year |
| INSPInspire Medical Systems | $4.62 | +166% a year |
| UFPTUFP Technologies | $9.28 | +8% a year |
| EYENational Vision | $0.61 | |
| CDRECadre | $0.81 | −14% a year |
| BVSBioventus | $0.77 | |
| ATRCAtriCure | $0.21 | |
| STAAStaar Surgical | $0.07 | |
| WRBYWarby Parker | $0.07 | |
| IRMDIradimed | $1.79 | +10% a year |
| Peer median | $0.79 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Establishment Labs
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.